https://www.selleckchem.com/
Vonafexor was overall well-tolerated and safe. The most frequent adverse events were moderate gastrointestinal events. Pruritus was more frequent with twice-daily compared to once-daily regimens (56-67% vs. 16%, respectively, p less then 0.05). Vonafexor monotherapy of 400mg once daily decreased HBsAg concentrations (-0.1 log10 IU/mL, p less then 0.05), and Vonafexor/pegylated-IFN-α2a combination therapy decreased HBcrAg and pgRNA. In conclusion, Vonafexor was safe with a decline in HBV-markers observed in CHB patients suggesting a potential antiviral effec
Like
Comment
Share
